Bioline Rx (BLRX)
Add to Watchlists Create an Alert
1.63
-0.05 -2.98%
NASDAQ
May 24, 8:00PM
BATS Real time
Currency in USD
Pro Data Export
Bioline Rx Key Statistics
Currency in USD
Current Valuation
Dividends and Shares
| Shares Outstanding | 22.26M |
| Dividend | |
| Dividend Yield | 0.00% |
| Cash Div. Payout Ratio TTM Pro | Go Pro |
| Payout Ratio TTM Pro | Go Pro |
| Latest Dividend Date | |
| Latest Ex-Dividend Date | |
| Last Split Factor | |
| Last Split Date |
Profitability
| Gross Profit Margin Quarterly | |
| Profit Margin Quarterly | |
| EBITDA Margin TTM Pro | Go Pro |
| Operating Margin TTM Pro | Go Pro |
Management Effectiveness
Liquidity and Solvency
| Altman Z-Score Pro | Go Pro |
| Current Ratio | 3.888 |
| Debt to Equity Ratio | 0.0007 |
| Free Cash Flow | -5.302M |
| KZ Index Pro | Go Pro |
| Tangible Common Equity Ratio Pro | Go Pro |
| Times Interest Earned TTM Pro | Go Pro |
Stock Price Performance
| Beta Pro | Go Pro |
| 1 Month Stock Returns | -12.37% |
| Year to Date Stock Returns | -35.57% |
| 1 Year Stock Returns | -35.83% |
| 3 Year Stock Returns | |
| 52 Week High | 5.10 |
| 52 Week Low | 1.55 |
Income Statement
Cash Flow Statement
| Cash from Financing TTM | 13.32M |
| Cash from Investing TTM | -4.189M |
| Cash from Operations TTM | -22.01M |
| Capital Expenditures Quarterly Pro | Go Pro |
Balance Sheet
| Cash and ST Investments | 28.20M |
| Long Term Debt | 0.0149M |
| Total Assets | 30.83M |
| Liabilities | 10.46M |
| Shareholders Equity | 20.37M |
| Book Value | 20.37M |
| Book Value Per Share | 0.9154 |
| Tangible Book Value Pro | Go Pro |
| Tangible Book Value Per Share Pro | Go Pro |
Earnings Quality
| Accruals Pro | Go Pro |
| Beneish M-Score Pro | Go Pro |
BLRX News
BioLineRx (BLRX) Enrolls First Patients in BL-8020 Phase I/II as HCV Treatment
Street Insider Apr 29
Street Insider Apr 29
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| BLRX | 1.63 | -0.05 | -2.98% | 36.28M |
New watchlist
